

Kevin J Harrington

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5274154/publications.pdf>

Version: 2024-02-01

148
papers

17,747
citations

46918

47
h-index

15683

125
g-index

152
all docs

152
docs citations

152
times ranked

18199
citing authors

#	ARTICLE	IF	CITATIONS
1	Triggering anti-GBM immune response with EGFR-mediated photoimmunotherapy. BMC Medicine, 2022, 20, 16.	2.3	15
2	Harnessing radiotherapy-induced NK-cell activity by combining DNA damage response inhibition and immune checkpoint blockade. , 2022, 10, e004306.		36
3	CD4 T cell dynamics shape the immune response to combination oncolytic herpes virus and BRAF inhibitor therapy for melanoma. , 2022, 10, e004410.		3
4	Pembrolizumab Alone or With Chemotherapy for Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma in KEYNOTE-048: Subgroup Analysis by Programmed Death Ligand-1 Combined Positive Score. Journal of Clinical Oncology, 2022, 40, 2321-2332.	0.8	79
5	Management of Head and Neck Mucosal Melanoma. Oral and Maxillofacial Surgery Clinics of North America, 2022, 34, 299-314.	0.4	2
6	Oncolytic virus mediated expansion of dual-specific CAR T cells improves efficacy against solid tumors in mice. Science Translational Medicine, 2022, 14, eabn2231.	5.8	70
7	Establishment of CORONET, COVID-19 Risk in Oncology Evaluation Tool, to Identify Patients With Cancer at Low Versus High Risk of Severe Complications of COVID-19 Disease On Presentation to Hospital. JCO Clinical Cancer Informatics, 2022, , .	1.0	7
8	Comparing programmed death ligand 1 scores for predicting pembrolizumab efficacy in head and neck cancer. Modern Pathology, 2021, 34, 532-541.	2.9	63
9	The Changing Landscape of Therapeutic Cancer Vaccines Novel Platforms and Neoantigen Identification. Clinical Cancer Research, 2021, 27, 689-703.	3.2	113
10	Oncolytic virotherapy induced CSDE1 neo-antigenesis restricts VSV replication but can be targeted by immunotherapy. Nature Communications, 2021, 12, 1930.	5.8	7
11	Avelumab plus standard-of-care chemoradiotherapy versus chemoradiotherapy alone in patients with locally advanced squamous cell carcinoma of the head and neck: a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial. Lancet Oncology, The, 2021, 22, 450-462.	5.1	287
12	On-treatment immune prognostic score for patients with relapsed and/or metastatic head and neck squamous cell carcinoma treated with immunotherapy. , 2021, 9, e002718.		23
13	Tipifarnib in Head and Neck Squamous Cell Carcinoma With HRAS Mutations. Journal of Clinical Oncology, 2021, 39, 1856-1864.	0.8	100
14	Acquired resistance to anti-MAPK targeted therapy confers an immune-evasive tumor microenvironment and cross-resistance to immunotherapy in melanoma. Nature Cancer, 2021, 2, 693-708.	5.7	102
15	Antiviral antibody responses to systemic administration of an oncolytic RNA virus: the impact of standard concomitant anticancer chemotherapies. , 2021, 9, e002673.		5
16	Abstract LB180: Clinical biomarker studies with two fusion-enhanced versions of oncolytic HSV (RP1) Tj ETQq0 0 0 rgBT /Overlock 10 Tf activation. Cancer Research, 2021, 81, LB180-LB180.	0.4	3
17	Dose-escalated intensity-modulated radiotherapy in patients with locally advanced laryngeal and hypopharyngeal cancers: ART DECO, a phase III randomised controlled trial. European Journal of Cancer, 2021, 153, 242-256.	1.3	7
18	Functional antibody and T cell immunity following SARS-CoV-2 infection, including by variants of concern, in patients with cancer: the CAPTURE study. Nature Cancer, 2021, 2, 1321-1337.	5.7	66

#	ARTICLE	IF	CITATIONS
19	Adaptive immunity and neutralizing antibodies against SARS-CoV-2 variants of concern following vaccination in patients with cancer: the CAPTURE study. <i>Nature Cancer</i> , 2021, 2, 1305-1320.	5.7	123
20	439â€¦A phase 2 study of evorpaccept (ALX148) in combination with pembrolizumab in patients with advanced head and neck squamous cell carcinoma (HNSCC); ASPEN-03. , 2021, 9, A469-A469.		0
21	Optimal acquisition scheme for flowâ€œcompensated intravoxel incoherent motion diffusionâ€œweighted imaging in the abdomen: An accurate and precise clinically feasible protocol. <i>Magnetic Resonance in Medicine</i> , 2020, 83, 1003-1015.	1.9	11
22	Head and neck mucosal melanoma: The United Kingdom national guidelines. <i>European Journal of Cancer</i> , 2020, 138, 11-18.	1.3	36
23	Immunomodulatory activity of IR700-labelled affibody targeting HER2. <i>Cell Death and Disease</i> , 2020, 11, 886.	2.7	20
24	Defining the true impact of coronavirus disease 2019 in the at-risk population of patients with cancer. <i>European Journal of Cancer</i> , 2020, 136, 99-106.	1.3	31
25	Current challenges for assessing the long-term clinical benefit of cancer immunotherapy: a multi-stakeholder perspective. , 2020, 8, e000648.		15
26	Talimogene Laherparepvec and Pembrolizumab in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (MASTERKEY-232): A Multicenter, Phase 1b Study. <i>Clinical Cancer Research</i> , 2020, 26, 5153-5161.	3.2	58
27	Combining BRAF inhibition with oncolytic herpes simplex virus enhances the immune-mediated antitumor therapy of BRAF-mutant thyroid cancer. , 2020, 8, e000698.		11
28	Inflammatory microenvironment remodelling by tumour cells after radiotherapy. <i>Nature Reviews Cancer</i> , 2020, 20, 203-217.	12.8	420
29	APOBEC3B-mediated corruption of the tumor cell immunopeptidome induces heteroclitic neoepitopes for cancer immunotherapy. <i>Nature Communications</i> , 2020, 11, 790.	5.8	47
30	Cost-effectiveness analysis of nivolumab for the treatment of squamous cell carcinoma of the head and neck in the United States. <i>Journal of Medical Economics</i> , 2020, 23, 442-447.	1.0	16
31	Impact of antibiotic use during curative treatment of locally advanced head and neck cancers with chemotherapy and radiotherapy. <i>European Journal of Cancer</i> , 2020, 131, 9-15.	1.3	44
32	Abstract LB-258: Efficacy of first-line (1L) pembrolizumab by PD-L1 combined positive score <1, 1-19, and â‰¥20 in recurrent and/or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC): KEYNOTE-048 subgroup analysis. <i>Cancer Research</i> , 2020, 80, LB-258-LB-258.	0.4	10
33	Abstract LB-104: Quantification of the preclinical and clinical relationship between pRAD50 and efficacy after treatment with the ATR inhibitor ceralasertib (AZD6738). , 2020, , .		0
34	408â€¦Phase I, first-in-human trial evaluating BI 1387446 (stimulator of interferon genes [STING] agonist) alone and combined with BI 754091 (anti-programmed cell death [PD]-1) in solid tumors. , 2020, , .		1
35	The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of squamous cell carcinoma of the head and neck (HNSCC). , 2019, 7, 184.		413
36	Optimizing oncolytic virotherapy in cancer treatment. <i>Nature Reviews Drug Discovery</i> , 2019, 18, 689-706.	21.5	325

#	ARTICLE	IF	CITATIONS
37	Plasmacytoid dendritic cells orchestrate innate and adaptive anti-tumor immunity induced by oncolytic coxsackievirus A21. , 2019, 7, 164.		27
38	Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study. Lancet, The, 2019, 394, 1915-1928.	6.3	1,804
39	Final analyses of OPTiM: a randomized phase III trial of talimogene laherparepvec versus granulocyte-macrophage colony-stimulating factor in unresectable stage III–IV melanoma. , 2019, 7, 145.		261
40	Afatinib vs Placebo as Adjuvant Therapy After Chemoradiotherapy in Squamous Cell Carcinoma of the Head and Neck. JAMA Oncology, 2019, 5, 1170.	3.4	34
41	Principal component analysis for fast and model-free denoising of multi b-value diffusion-weighted MR images. Physics in Medicine and Biology, 2019, 64, 105015.	1.6	22
42	Suboptimal T-cell Therapy Drives a Tumor Cell Mutator Phenotype That Promotes Escape from First-Line Treatment. Cancer Immunology Research, 2019, 7, 828-840.	1.6	13
43	ATR Inhibition Potentiates the Radiation-induced Inflammatory Tumor Microenvironment. Clinical Cancer Research, 2019, 25, 3392-3403.	3.2	144
44	Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study. Lancet, The, 2019, 393, 156-167.	6.3	1,153
45	Protocol-specified final analysis of the phase 3 KEYNOTE-048 trial of pembrolizumab (pembro) as first-line therapy for recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC).. Journal of Clinical Oncology, 2019, 37, 6000-6000.	0.8	118
46	Pembrolizumab (pembro) for recurrent head and neck squamous cell carcinoma (HNSCC): Post hoc analyses of phase 3 KEYNOTE-040 prior radiation treatment (RT) and disease state.. Journal of Clinical Oncology, 2019, 37, 6026-6026.	0.8	2
47	An open label, multicenter, phase I/II study of RP1 as a single agent and in combination with PD1 blockade in patients with solid tumors.. Journal of Clinical Oncology, 2019, 37, TPS2671-TPS2671.	0.8	2
48	Progression-free survival (PFS) in unresectable melanoma patients (pts) treated with talimogene laherparepvec (T-VEC) versus granulocyte macrophage colony-stimulating factor (GM-CSF) in OPTiM.. Journal of Clinical Oncology, 2019, 37, 9524-9524.	0.8	3
49	NUT Carcinoma of the Salivary Glands. American Journal of Surgical Pathology, 2018, 42, 877-884.	2.1	44
50	Near–infrared photoimmunotherapy targeting EGFR– Shedding new light on glioblastoma treatment. International Journal of Cancer, 2018, 142, 2363-2374.	2.3	47
51	Intravenous delivery of oncolytic reovirus to brain tumor patients immunologically primes for subsequent checkpoint blockade. Science Translational Medicine, 2018, 10, .	5.8	288
52	Oncolytic reovirus as a combined antiviral and anti-tumour agent for the treatment of liver cancer. Gut, 2018, 67, 562-573.	6.1	49
53	Warthin Tumor–Like Mucoepidermoid Carcinoma. International Journal of Surgical Pathology, 2018, 26, 31-33.	0.4	16
54	Dosimetric Implications of Computerised Tomography-Only versus Magnetic Resonance-Fusion Contouring in Stereotactic Body Radiotherapy for Prostate Cancer. Medicines (Basel, Switzerland), 2018, 5, 32.	0.7	5

#	ARTICLE	IF	CITATIONS
55	Results of a multicentre randomised controlled trial of cochlear-sparing intensity-modulated radiotherapy versus conventional radiotherapy in patients with parotid cancer (COSTAR); TJ ETQq1 1 0.784314 rgBI.3 Overlock 110 Tf 50	1.0	10
56	APOBEC3 Mediates Resistance to Oncolytic Viral Therapy. <i>Molecular Therapy - Oncolytics</i> , 2018, 11, 1-13.	2.0	14
57	Targeting ATR for Cancer Therapy: ATR-Targeted Drug Candidates. <i>Cancer Drug Discovery and Development</i> , 2018, , 99-127.	0.2	1
58	Abstract CT115: Updated survival results of the KEYNOTE-040 study of pembrolizumab vs standard-of-care chemotherapy for recurrent or metastatic head and neck squamous cell carcinoma. <i>Cancer Research</i> , 2018, 78, CT115-CT115.	0.4	21
59	Abstract CT118: PK-Biomarker-Safety modelling aids choice of recommended Phase II dose and schedule for AZD6738 (ATR inhibitor). <i>Cancer Research</i> , 2018, 78, CT118-CT118.	0.4	7
60	Nivolumab (nivo) vs investigator's choice (IC) in patients (pts) with recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN): Analysis of CheckMate 141 by age.. <i>Journal of Clinical Oncology</i> , 2018, 36, 6028-6028.	0.8	9
61	Safety and preliminary efficacy of talimogene laherparepvec (T-VEC) in combination (combo) with pembrolizumab (Pembro) in patients (pts) with recurrent or metastatic squamous cell carcinoma of the head and neck (R/M HNSCC): A multicenter, phase 1b study (MASTERKEY-232).. <i>Journal of Clinical Oncology</i> , 2018, 36, 6036-6036.	0.8	20
62	Randomized phase 2 trial of patritumab (P) or placebo (PBO) + cetuximab (C) + cisplatin (CIS) or carboplatin (CAR) for recurrent and/or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN).. <i>Journal of Clinical Oncology</i> , 2018, 36, 6045-6045.	0.8	7
63	A phase 3, randomized, open-label study of epacadostat plus pembrolizumab, pembrolizumab monotherapy, and the EXTREME regimen as first-line treatment for recurrent/metastatic head and neck squamous cell carcinoma (R/M SCCHN): ECHO-304/KEYNOTE-669.. <i>Journal of Clinical Oncology</i> , 2018, 36, TPS6090-TPS6090.	0.8	14
64	Molecular prediction of lymph node metastases using immunohistochemical analysis of primary oral tongue squamous cell carcinomas.. <i>Journal of Clinical Oncology</i> , 2018, 36, 6054-6054.	0.8	0
65	Hope for salivary gland cancer (SGC): EORTC HNSCG/UKCRN 1206 randomized phase II study to evaluate the efficacy and safety of chemotherapy (CT) vs androgen deprivation therapy (ADT) in patients with recurrent and/or metastatic androgen receptor (AR) expressing SGC (NCT01969578).. <i>Journal of Clinical Oncology</i> , 2018, 36, TPS6099-TPS6099.	0.8	0
66	Abstract 4162: Lentivirally delivered shRNA knockdown of CXCL12 is effective at preventing radiation fibrosis in normal tissues. , 2018, , .		0
67	Abstract CT116: Nivolumab (Nivo) vs investigator's choice (IC) in recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN): 2-yr outcomes in the overall population and PD-L1 subgroups of CheckMate 141. <i>Cancer Research</i> , 2018, 78, CT116-CT116.	0.4	4
68	A randomised controlled trial of Caphosol mouthwash in management of radiation-induced mucositis in head and neck cancer. <i>Radiotherapy and Oncology</i> , 2017, 122, 207-211.	0.3	27
69	Radiosensitization by the ATR Inhibitor AZD6738 through Generation of Acentric Micronuclei. <i>Molecular Cancer Therapeutics</i> , 2017, 16, 25-34.	1.9	93
70	The emerging potential of magnetic resonance imaging in personalizing radiotherapy for head and neck cancer: an oncologist's perspective. <i>British Journal of Radiology</i> , 2017, 90, 20160768.	1.0	39
71	Subversion of NK-cell and TNF α Immune Surveillance Drives Tumor Recurrence. <i>Cancer Immunology Research</i> , 2017, 5, 1029-1045.	1.6	22
72	Nivolumab versus standard, single-agent therapy of investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck (CheckMate 141): health-related quality-of-life results from a randomised, phase 3 trial. <i>Lancet Oncology</i> , The, 2017, 18, 1104-1115.	5.1	325

#	ARTICLE	IF	CITATIONS
73	Combining Molecularly Targeted Agents: Is More Always Better?. <i>Clinical Cancer Research</i> , 2017, 23, 1123-1125.	3.2	6
74	Blood transfusion during radical chemo-radiotherapy does not reduce tumour hypoxia in squamous cell cancer of the head and neck. <i>British Journal of Cancer</i> , 2017, 116, 28-35.	2.9	20
75	Evidence-Based Treatment Options in Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck. <i>Frontiers in Oncology</i> , 2017, 7, 72.	1.3	122
76	A practical guide to the handling and administration of talimogene laherparepvec in Europe. <i>OncoTargets and Therapy</i> , 2017, Volume 10, 3867-3880.	1.0	33
77	Characterization of potential predictive biomarkers of response to nivolumab in CheckMate 141 in patients with squamous cell carcinoma of the head and neck (SCCHN).. <i>Journal of Clinical Oncology</i> , 2017, 35, 6050-6050.	0.8	7
78	Characterization of potential predictive biomarkers of response to nivolumab in CheckMate-141 in patients with squamous cell carcinoma of the head and neck (SCCHN).. <i>Journal of Clinical Oncology</i> , 2017, 35, 5-5.	0.8	1
79	Predicting response to radical (chemo)radiotherapy (R-CRT) with circulating HPV DNA and tumor DNA (ctDNA) analysis in locally-advanced head and neck squamous cell carcinoma (LAHNC).. <i>Journal of Clinical Oncology</i> , 2017, 35, 6043-6043.	0.8	0
80	Abstract CT084: A Phase I dose-escalation study of ATR inhibitor monotherapy with AZD6738 in advanced solid tumors (PATRIOT Part A). <i>Cancer Research</i> , 2017, 77, CT084-CT084.	0.4	8
81	Efficacy and safety of talimogene laherparepvec versus granulocyte-macrophage colony-stimulating factor in patients with stage IIIB/C and IVM1a melanoma: subanalysis of the Phase III OPTiM trial. <i>OncoTargets and Therapy</i> , 2016, Volume 9, 7081-7093.	1.0	83
82	The MRI-Linear Accelerator Consortium: Evidence-Based Clinical Introduction of an Innovation in Radiation Oncology Connecting Researchers, Methodology, Data Collection, Quality Assurance, and Technical Development. <i>Frontiers in Oncology</i> , 2016, 6, 215.	1.3	100
83	63. Immunogenicity of Self Tumor Associated Antigens Is Enhanced Through Protein Truncation. <i>Molecular Therapy</i> , 2016, 24, S28.	3.7	0
84	Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck. <i>New England Journal of Medicine</i> , 2016, 375, 1856-1867.	13.9	3,845
85	Cutaneous head and neck melanoma in OPTiM, a randomized phase 3 trial of talimogene laherparepvec versus granulocyte-macrophage colony-stimulating factor for the treatment of unresected stage IIIB/IIIC/IV melanoma. <i>Head and Neck</i> , 2016, 38, 1752-1758.	0.9	49
86	Contrast enhancement of carotid adventitial vasa vasorum as a biomarker of radiation-induced atherosclerosis. <i>Radiotherapy and Oncology</i> , 2016, 120, 63-68.	0.3	7
87	CHK1 Inhibition Radiosensitizes Head and Neck Cancers to Paclitaxel-Based Chemoradiotherapy. <i>Molecular Cancer Therapeutics</i> , 2016, 15, 2042-2054.	1.9	46
88	Carotid intima-medial thickness as a marker of radiation-induced carotid atherosclerosis. <i>Radiotherapy and Oncology</i> , 2016, 118, 323-329.	0.3	18
89	Plaque Neovascularization Is Increased in Human Carotid Atherosclerosis Related to Prior Neck Radiotherapy. <i>JACC: Cardiovascular Imaging</i> , 2016, 9, 668-675.	2.3	14
90	Reply to N.F. Saba and S.J. Wong. <i>Journal of Clinical Oncology</i> , 2016, 34, 2073-2074.	0.8	0

#	ARTICLE	IF	CITATIONS
91	Acoustic parameters of speech: Lack of correlation with perceptual and questionnaire-based speech evaluation in patients with oral and oropharyngeal cancer treated with primary surgery. <i>Head and Neck</i> , 2016, 38, 670-676.	0.9	10
92	Arterial Stiffness as a Biomarker of Radiation-Induced Carotid Atherosclerosis. <i>Angiology</i> , 2016, 67, 266-271.	0.8	21
93	Contrast-enhanced ultrasound to assess plaque neovascularization in irradiated carotid arteries. <i>International Journal of Cardiology</i> , 2016, 202, 3-4.	0.8	3
94	First results of COSTAR: A randomised trial of 3-dimensional conformal radiotherapy (3DCRT) vs cochlea-sparing intensity modulated radiotherapy (CS-IMRT) in patients with parotid cancer.. <i>Journal of Clinical Oncology</i> , 2016, 34, 6006-6006.	0.8	1
95	Further evaluations of nivolumab (nivo) versus investigator's choice (IC) chemotherapy for recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN): CheckMate 141.. <i>Journal of Clinical Oncology</i> , 2016, 34, 6009-6009.	0.8	32
96	Phase I/II canon study: Oncolytic immunotherapy for the treatment of non-muscle invasive bladder (NMIBC) cancer using intravesical coxsackievirus A21.. <i>Journal of Clinical Oncology</i> , 2016, 34, e16016-e16016.	0.8	5
97	PATRIOT: A phase I study to assess the tolerability, safety and biological effects of a specific ataxia telangiectasia and Rad3-related (ATR) inhibitor (AZD6738) as a single agent and in combination with palliative radiation therapy in patients with solid tumours.. <i>Journal of Clinical Oncology</i> , 2016, 34, TPS2603-TPS2603.	0.8	2
98	Phase I STORM study (KEYNOTE 200): Intravenous delivery of a novel oncolytic immunotherapy agent, Coxsackievirus A21 in combination with pembrolizumab in advanced cancer patients.. <i>Journal of Clinical Oncology</i> , 2016, 34, TPS3108-TPS3108.	0.8	3
99	Patritumab (P) or placebo (PBO) plus cetuximab (C) and platinum-based therapy in squamous cell carcinoma of the head and neck (SCCHN): a phase 2 study.. <i>Journal of Clinical Oncology</i> , 2016, 34, TPS6104-TPS6104.	0.8	2
100	ORCA-2: A phase I study of olaparib in addition to cisplatin-based concurrent chemoradiotherapy for patients with high risk locally advanced squamous cell carcinoma of the head and neck.. <i>Journal of Clinical Oncology</i> , 2016, 34, TPS6108-TPS6108.	0.8	4
101	Oncolytic vaccinia virus combined with radiotherapy induces apoptotic cell death in sarcoma cells by down-regulating the inhibitors of apoptosis. <i>Oncotarget</i> , 2016, 7, 81208-81222.	0.8	22
102	69. Combination Therapy of Reovirus and PD-1 Blockade Effectively Establishes Tumor Control Via Innate and Adaptive Immune Responses. <i>Molecular Therapy</i> , 2015, 23, S30.	3.7	2
103	Comparison of CT number calibration techniques for CBCT-based dose calculation. <i>Strahlentherapie Und Onkologie</i> , 2015, 191, 970-978.	1.0	66
104	Phase I/II storm study: Intravenous delivery of a novel oncolytic immunotherapy agent, Coxsackievirus A21, in advanced cancer patients. , 2015, 3, P341.		4
105	Brain-Sparing Methods for IMRT of Head and Neck Cancer. <i>PLoS ONE</i> , 2015, 10, e0120141.	1.1	19
106	BRAF- and MEK-Targeted Small Molecule Inhibitors Exert Enhanced Antimelanoma Effects in Combination With Oncolytic Reovirus Through ER Stress. <i>Molecular Therapy</i> , 2015, 23, 931-942.	3.7	44
107	Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma. <i>Journal of Clinical Oncology</i> , 2015, 33, 2780-2788.	0.8	1,988
108	Mutated BRAF Emerges as a Major Effector of Recurrence in a Murine Melanoma Model After Treatment With Immunomodulatory Agents. <i>Molecular Therapy</i> , 2015, 23, 845-856.	3.7	11

#	ARTICLE	IF	CITATIONS
109	The tumour microenvironment after radiotherapy: mechanisms of resistance and recurrence. <i>Nature Reviews Cancer</i> , 2015, 15, 409-425.	12.8	1,474
110	Attenuation Correction and Normalisation for Quantification of Contrast Enhancement in Ultrasound Images of Carotid Arteries. <i>Ultrasound in Medicine and Biology</i> , 2015, 41, 1876-1883.	0.7	10
111	Phase I Trial of Cyclophosphamide as an Immune Modulator for Optimizing Oncolytic Reovirus Delivery to Solid Tumors. <i>Clinical Cancer Research</i> , 2015, 21, 1305-1312.	3.2	40
112	Evaluation of the Risk of Grade 3 Oral and Pharyngeal Dysphagia Using Atlas-Based Method and Multivariate Analyses of Individual Patient Dose Distributions. <i>International Journal of Radiation Oncology Biology Physics</i> , 2015, 93, 507-515.	0.4	36
113	Human Papillomavirus-Positive Pharyngeal Cancer. <i>Journal of Clinical Oncology</i> , 2015, 33, 3251-3261.	0.8	47
114	Abstract CT205: Intravenous delivery of a novel oncolytic immunotherapy agent, CAVATAK, in advanced cancer patients. <i>Cancer Research</i> , 2015, 75, CT205-CT205.	0.4	3
115	KEYNOTE-040: A phase III randomized trial of pembrolizumab (MK-3475) versus standard treatment in patients with recurrent or metastatic head and neck cancer.. <i>Journal of Clinical Oncology</i> , 2015, 33, TPS6084-TPS6084.	0.8	20
116	Abstract 1360: Combination therapy of reovirus and PD-1 blockade effectively establishes tumor control via innate and adaptive immune responses. , 2015, , .		2
117	Applications of coxsackievirus A21 in oncology. <i>Oncolytic Virotherapy</i> , 2014, 3, 47.	6.0	84
118	A Recombinant Modified Vaccinia Ankara Vaccine Encoding Epstein-Barr Virus (EBV) Target Antigens: A Phase I Trial in UK Patients with EBV-Positive Cancer. <i>Clinical Cancer Research</i> , 2014, 20, 5009-5022.	3.2	139
119	Cytokine Conditioning Enhances Systemic Delivery and Therapy of an Oncolytic Virus. <i>Molecular Therapy</i> , 2014, 22, 1851-1863.	3.7	60
120	Radiation-induced carotid artery atherosclerosis. <i>Radiotherapy and Oncology</i> , 2014, 110, 31-38.	0.3	115
121	The Profile of Tumor Antigens Which Can be Targeted by Immunotherapy Depends Upon the Tumor's Anatomical Site. <i>Molecular Therapy</i> , 2014, 22, 1936-1948.	3.7	14
122	Multiple cervical lymph node involvement and extra-capsular extension predict for contralateral nodal recurrence after ipsilateral radiotherapy for squamous cell carcinoma of the tonsil. <i>Oral Oncology</i> , 2014, 50, 901-906.	0.8	37
123	Final long-term results of a phase I/II study of dose-escalated intensity-modulated radiotherapy for locally advanced laryngo-hypopharyngeal cancers. <i>Oral Oncology</i> , 2014, 50, 1089-1097.	0.8	21
124	Treatment-related dysgeusia in head and neck cancer patients. <i>Cancer Treatment Reviews</i> , 2014, 40, 1106-1117.	3.4	57
125	Oncolytic wild-type reovirus infection in brain tumors following intravenous administration in patients.. <i>Journal of Clinical Oncology</i> , 2014, 32, 3104-3104.	0.8	1
126	Final analysis: A randomized, blinded, placebo (P)-controlled phase III study of adjuvant postoperative lapatinib (L) with concurrent chemotherapy and radiation therapy (CH-RT) in high-risk patients with squamous cell carcinoma of the head and neck (SCCHN).. <i>Journal of Clinical Oncology</i> , 2014, 32, 6005-6005.	0.8	17

#	ARTICLE	IF	CITATIONS
127	Detecting and targeting tumor relapse by its resistance to innate effectors at early recurrence. <i>Nature Medicine</i> , 2013, 19, 1625-1631.	15.2	52
128	Randomised Phase II study of oral lapatinib combined with chemoradiotherapy in patients with advanced squamous cell carcinoma of the head and neck: Rationale for future randomised trials in human papilloma virus-negative disease. <i>European Journal of Cancer</i> , 2013, 49, 1609-1618.	1.3	103
129	A novel serum protein signature associated with resistance to epidermal growth factor receptor tyrosine kinase inhibitors in head and neck squamous cell carcinoma. <i>European Journal of Cancer</i> , 2013, 49, 2512-2521.	1.3	11
130	Functional Cloning of Recurrence-specific Antigens Identifies Molecular Targets to Treat Tumor Relapse. <i>Molecular Therapy</i> , 2013, 21, 1507-1516.	3.7	35
131	Phase I/II Trial of Carboplatin and Paclitaxel Chemotherapy in Combination with Intravenous Oncolytic Reovirus in Patients with Advanced Malignancies. <i>Clinical Cancer Research</i> , 2012, 18, 2080-2089.	3.2	151
132	Phase II Trial of Intravenous Administration of Reolysin [®] (Reovirus Serotype-3-dearing Strain) in Patients with Metastatic Melanoma. <i>Molecular Therapy</i> , 2012, 20, 1998-2003.	3.7	135
133	Cell Carriage, Delivery, and Selective Replication of an Oncolytic Virus in Tumor in Patients. <i>Science Translational Medicine</i> , 2012, 4, 138ra77.	5.8	142
134	Novel approaches to improve the therapeutic index of head and neck radiotherapy: An analysis of data from the PARSPORT randomised phase III trial. <i>Radiotherapy and Oncology</i> , 2012, 103, 82-87.	0.3	65
135	Reovirus exerts potent oncolytic effects in head and neck cancer cell lines that are independent of signalling in the EGFR pathway. <i>BMC Cancer</i> , 2012, 12, 368.	1.1	49
136	Using virally expressed melanoma cDNA libraries to identify tumor-associated antigens that cure melanoma. <i>Nature Biotechnology</i> , 2012, 30, 337-343.	9.4	98
137	Broad antigenic coverage induced by vaccination with virus-based cDNA libraries cures established tumors. <i>Nature Medicine</i> , 2011, 17, 854-859.	15.2	86
138	Synergistic effects of oncolytic reovirus and docetaxel chemotherapy in prostate cancer. <i>BMC Cancer</i> , 2011, 11, 221.	1.1	52
139	Vesicular Stomatitis Virus-induced Immune Suppressor Cells Generate Antagonism Between Intratumoral Oncolytic Virus and Cyclophosphamide. <i>Molecular Therapy</i> , 2011, 19, 140-149.	3.7	30
140	A Phase I Study of the Combination of Intravenous Reovirus Type 3 Dearing and Gemcitabine in Patients with Advanced Cancer. <i>Clinical Cancer Research</i> , 2011, 17, 581-588.	3.2	102
141	Abstract 3100: HOX transcription factors promote cell survival in breast cancer. <i>Cancer Research</i> , 2011, 71, 3100-3100.	0.4	1
142	Using a Bayesian Feature-selection Algorithm to Identify Dose-response Models Based on the Shape of the 3D Dose-distribution: An Example from a Head-and-neck Cancer Trial. , 2010, , .		3
143	REO-10: A Phase I Study of Intravenous Reovirus and Docetaxel in Patients with Advanced Cancer. <i>Clinical Cancer Research</i> , 2010, 16, 5564-5572.	3.2	120
144	Improved Systemic Delivery of Oncolytic Reovirus to Established Tumors Using Preconditioning with Cyclophosphamide-Mediated Treg Modulation and Interleukin-2. <i>Clinical Cancer Research</i> , 2009, 15, 561-569.	3.2	63

#	ARTICLE	IF	CITATIONS
145	Synergistic Effects of Oncolytic Reovirus and Cisplatin Chemotherapy in Murine Malignant Melanoma. <i>Clinical Cancer Research</i> , 2009, 15, 6158-6166.	3.2	83
146	Cyclophosphamide Facilitates Antitumor Efficacy against Subcutaneous Tumors following Intravenous Delivery of Reovirus. <i>Clinical Cancer Research</i> , 2008, 14, 259-269.	3.2	156
147	A Phase I Study of Intravenous Oncolytic Reovirus Type 3 Dearing in Patients with Advanced Cancer. <i>Clinical Cancer Research</i> , 2008, 14, 7127-7137.	3.2	205
148	MET and RON Receptor Tyrosine Kinases: Novel Therapeutic Targets in Squamous Cell Carcinoma of the Head and Neck. <i>Current Enzyme Inhibition</i> , 2007, 3, 1-12.	0.3	2